Heidelberg Pharma AG
XMUN:HPHA
Heidelberg Pharma AG
XMUN:HPHA
Price:
2.73
EUR
Market Closed
Market Cap:
€127.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
H
|
Heidelberg Pharma AG
XMUN:HPHA
|
DE |
|
K
|
Kumba Iron Ore Ltd
JSE:KIO
|
ZA |
|
E
|
Eli Lilly and Co
XHAM:LLY
|
US |
|
M
|
Meta Platforms Inc
F:FB2A
|
US |
|
L
|
Las Vegas Sands Corp
XMUN:LCR
|
US |
|
Iberdrola SA
F:IBE5
|
ES |
|
Scor SE
PAR:SCR
|
FR |
|
S
|
Suzuki Motor Corp
F:SUK
|
JP |
|
Y
|
Yara International ASA
XMUN:IU2
|
NO |
|
M
|
Macy's Inc
F:FDO
|
US |
|
F
|
Fairfax Financial Holdings Ltd
SWB:FFX
|
CA |
|
P
|
PNC Financial Services Group Inc
F:PNP
|
US |
|
Threat Protect Australia Ltd
ASX:TPS
|
AU |
|
S
|
Stellantis NV
DUS:8TI
|
NL |
|
Chocoladefabriken Lindt & Spruengli AG
OTC:LDSVF
|
CH |
|
N
|
Nutrien Ltd
NYSE:NTR
|
CA |
|
Shimamura Co Ltd
OTC:SHAOF
|
JP |
|
A
|
Analog Devices Inc
DUS:ANL
|
US |
|
N
|
NTT Data Corp
OTC:NTTDF
|
JP |
|
B
|
Build-A-Bear Workshop Inc
F:FPW
|
US |
|
S
|
Supernus Pharmaceuticals Inc
SWB:S49
|
US |
|
V
|
Vodafone Group PLC
DUS:VODI
|
UK |
|
H
|
Hero MotoCorp Ltd
BSE:500182
|
IN |
|
A
|
Apple Inc
XBER:APC
|
US |
Cash Flow Statement
Cash Flow Statement
Heidelberg Pharma AG
Heidelberg Pharma AG
Currency: EUR
| Feb-2020 | May-2020 | Aug-2020 | Nov-2020 | Feb-2021 | May-2021 | Aug-2021 | Nov-2021 | Feb-2022 | May-2022 | Aug-2022 | Nov-2022 | Feb-2023 | May-2023 | Aug-2023 | Nov-2023 | Feb-2024 | May-2024 | Aug-2024 | Nov-2024 | Feb-2025 | May-2025 | Aug-2025 | Nov-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||||||
| Net Income |
(15)
|
(15)
|
(17)
|
(18)
|
(20)
|
(22)
|
(25)
|
(26)
|
(27)
|
(22)
|
(21)
|
(20)
|
(19)
|
(27)
|
(22)
|
(20)
|
(18)
|
(13)
|
(19)
|
(19)
|
(21)
|
(23)
|
(26)
|
(42)
|
|
| Depreciation & Amortization |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
|
| Stock-Based Compensation |
1
|
1
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Other Non-Cash Items |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
(6)
|
(4)
|
(4)
|
(5)
|
2
|
0
|
1
|
(2)
|
(3)
|
7
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
(0)
|
3
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(2)
|
(2)
|
13
|
11
|
10
|
5
|
(8)
|
(7)
|
(10)
|
(12)
|
(16)
|
(14)
|
(11)
|
(8)
|
(2)
|
(3)
|
1
|
|
| Cash from Operating Activities |
(13)
N/A
|
(11)
+16%
|
(17)
-49%
|
(18)
-8%
|
(20)
-11%
|
(23)
-14%
|
(23)
-3%
|
(27)
-14%
|
(27)
+0%
|
(6)
+76%
|
(8)
-31%
|
(9)
-5%
|
(13)
-48%
|
(34)
-161%
|
(34)
0%
|
(34)
+1%
|
(34)
0%
|
(32)
+4%
|
(30)
+8%
|
(30)
+1%
|
(27)
+7%
|
(27)
+2%
|
(32)
-18%
|
(32)
+0%
|
|
| Investing Cash Flow | |||||||||||||||||||||||||
| Capital Expenditures |
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
7
|
7
|
0
|
0
|
0
|
0
|
(0)
|
0
|
|
| Cash from Investing Activities |
(1)
N/A
|
(1)
+14%
|
(1)
-2%
|
(1)
-12%
|
(1)
-8%
|
(1)
-3%
|
(1)
-4%
|
(1)
+6%
|
(1)
+25%
|
(1)
+37%
|
(1)
+24%
|
(1)
-18%
|
(1)
-36%
|
(1)
-53%
|
6
N/A
|
6
+5%
|
6
+4%
|
7
+7%
|
(0)
N/A
|
(0)
-56%
|
(1)
-18%
|
(0)
+16%
|
(0)
+19%
|
(0)
+63%
|
|
| Financing Cash Flow | |||||||||||||||||||||||||
| Net Issuance of Common Stock |
0
|
14
|
14
|
14
|
0
|
0
|
20
|
20
|
0
|
20
|
0
|
80
|
0
|
80
|
80
|
0
|
0
|
0
|
0
|
23
|
0
|
0
|
23
|
19
|
|
| Net Issuance of Debt |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
10
|
10
|
10
|
15
|
5
|
5
|
5
|
(5)
|
(5)
|
(10)
|
(10)
|
(5)
|
(10)
|
(5)
|
(5)
|
(5)
|
(0)
|
(0)
|
(0)
|
|
| Other |
0
|
(0)
|
(0)
|
(0)
|
5
|
(0)
|
(1)
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
(1)
|
(1)
|
0
|
0
|
21
|
21
|
(2)
|
0
|
(5)
|
(5)
|
(0)
|
|
| Cash from Financing Activities |
(0)
N/A
|
14
N/A
|
14
0%
|
14
+0%
|
19
+35%
|
10
-48%
|
29
+193%
|
29
0%
|
29
+0%
|
24
-17%
|
5
-80%
|
84
+1 610%
|
74
-12%
|
74
+0%
|
69
-7%
|
(10)
N/A
|
(5)
+50%
|
11
N/A
|
16
+45%
|
16
+0%
|
16
0%
|
18
+12%
|
18
+2%
|
18
0%
|
|
| Change in Cash | |||||||||||||||||||||||||
| Effect of Foreign Exchange Rates |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
|
| Net Change in Cash |
(15)
N/A
|
2
N/A
|
(3)
N/A
|
(5)
-41%
|
(2)
+59%
|
(14)
-614%
|
4
N/A
|
1
-73%
|
2
+38%
|
17
+968%
|
(3)
N/A
|
75
N/A
|
60
-20%
|
39
-35%
|
40
+2%
|
(38)
N/A
|
(32)
+15%
|
(15)
+54%
|
(14)
+4%
|
(14)
+1%
|
(12)
+15%
|
(9)
+22%
|
(14)
-46%
|
(14)
-5%
|
|
| Free Cash Flow | |||||||||||||||||||||||||
| Free Cash Flow |
(14)
N/A
|
(12)
+16%
|
(18)
-45%
|
(19)
-9%
|
(21)
-11%
|
(24)
-14%
|
(25)
-3%
|
(28)
-12%
|
(28)
+1%
|
(7)
+74%
|
(9)
-26%
|
(9)
-6%
|
(14)
-47%
|
(35)
-154%
|
(35)
0%
|
(35)
+2%
|
(34)
+1%
|
(33)
+5%
|
(30)
+7%
|
(30)
+1%
|
(28)
+7%
|
(27)
+3%
|
(32)
-17%
|
(32)
+1%
|
|
Switch to:
Switch to:
See Also
Other Heidelberg Pharma AG listings:
Discover More
